SIRPα: A key player in innate immunity.
CD47
Cancer immunology
Diseases
Innate immunity
SIRPα
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
15
07
2023
received:
01
03
2023
accepted:
05
09
2023
medline:
2
11
2023
pubmed:
6
9
2023
entrez:
6
9
2023
Statut:
ppublish
Résumé
Signal regulatory protein alpha (SIRPα) is a crucial inhibitory regulator expressed on the surface of myeloid cells, including macrophages, dendritic cells, monocytes, neutrophils, and microglia. SIRPα plays an indispensable role in innate immune and adoptive immune responses in cancer immunology, tissue homeostasis, and other physiological or phycological conditions. This review provides an overview of the research history, ligands, signal transduction pathways, and functional mechanisms associated with SIRPα. Additionally, we summarize the therapeutic implications of targeting SIRPα as a promising novel strategy in immuno-oncology.
Identifiants
pubmed: 37672390
doi: 10.1002/eji.202350375
doi:
Substances chimiques
Antigens, Differentiation
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2350375Informations de copyright
© 2023 Wiley-VCH GmbH.
Références
Sano, S., Matsuda, Y. and Nakagawa, H., A novel brain-specific antigen: a glycoprotein electrophoretically similar to but immunochemically different from type B nucleoside diphosphatase. J. Biochem. 1989. 105: 457-460.
Sano, S., Ohnishi, H. and Kubota, M., Gene structure of mouse BIT/SHPS-1. Biochem. J. 1999. 344 Pt: 667-675.
Noguchi, T., Matozaki, T., Fujioka, Y., Yamao, T., Tsuda, M., Takada, T. and Kasuga, M., Characterization of a 115-kDa protein that binds to SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in Chinese hamster ovary cells. J. Biol. Chem. 1996. 271: 27652-27658.
Comu, S., Weng, W., Olinsky, S., Ishwad, P., Mi, Z., Hempel, J., Watkins, S. et al., The murine P84 neural adhesion molecule is SHPS-1, a member of the phosphatase-binding protein family. J. Neurosci. 1997. 17: 8702-8710.
Fujioka, Y., Matozaki, T., Noguchi, T., Iwamatsu, A., Yamao, T., Takahashi, N., Tsuda, M. et al., A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion. Mol. Cell. Biol. 1996. 16: 6887-6899.
Veillette, A., Thibaudeau, E. and Latour, S., High expression of inhibitory receptor SHPS-1 and its association with protein-tyrosine phosphatase SHP-1 in macrophages. J. Biol. Chem. 1998. 273: 22719-22728.
Tsuda, M., Matozaki, T., Fukunaga, K., Fujioka, Y., Imamoto, A., Noguchi, T., Takada, T. et al., Integrin-mediated tyrosine phosphorylation of SHPS-1 and its association with SHP-2. Roles of Fak and Src family kinases. J. Biol. Chem. 1998. 273: 13223-13229.
Jiang, P., Lagenaur, C. F. and Narayanan, V., Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J. Biol. Chem. 1999. 274: 559-562.
Vernon-Wilson, E. F., Kee, W. J., Willis, A. C., Barclay, A. N., Simmons, D. L. and Brown, M. H., CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPalpha 1. Eur. J. Immunol. 2000. 30: 2130-2137.
Han, X., Sterling, H., Chen, Y., Saginario, C., Brown, E. J., Frazier, W. A. et al., CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J. Biol. Chem. 2000. 275: 37984-37992.
Brown, E. J. and Frazier, W. A., Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001. 11: 130-135.
Ishikawa-Sekigami, T., Kaneko, Y., Okazawa, H., Tomizawa, T., Okajo, J., Saito, Y., Okuzawa, C. et al., SHPS-1 promotes the survival of circulating erythrocytes through inhibition of phagocytosis by splenic macrophages. Blood 2006. 107: 341-348.
Barclay, A. N. and Brown, M. H., The SIRP family of receptors and immune regulation. Nat. Rev. Immunol. 2006. 6: 457-464.
Matozaki, T., Murata, Y., Okazawa, H. and Ohnishi, H., Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol. 2009. 19: 72-80.
Dietrich, J., Cella, M., Seiffert, M., Bühring, H. J. and Colonna, M., Cutting edge: signal-regulatory protein beta 1 is a DAP12-associated activating receptor expressed in myeloid cells. J. Immunol. 2000. 164: 9-12.
van Beek, E. M., Cochrane, F., Barclay, A. N. and van den Berg, T. K., Signal regulatory proteins in the immune system. J. Immunol. 2005. 175: 7781-7787.
Brooke, G., Holbrook, J. D., Brown, M. H. and Barclay, A. N., Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family. J. Immunol. 2004. 173: 2562-2570.
Lee, W. Y., Weber, D. A., Laur, O., Severson, E. A., McCall, I., Jen, R. P., Chin, A. C. et al., Novel structural determinants on SIRP alpha that mediate binding to CD47. J. Immunol. 2007. 179: 7741-7750.
Wu, Z., Weng, L., Zhang, T., Tian, H., Fang, L., Teng, H. et al., Identification of glutaminyl cyclase isoenzyme isoQC as a regulator of SIRPα-CD47 axis. Cell Res. 2019. 29: 502-505.
Hatherley, D., Graham, S. C., Turner, J., Harlos, K., Stuart, D. I. and Barclay, A. N., Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. Mol. Cell 2008. 31: 266-277.
Hatherley, D., Lea, S. M., Johnson, S. and Barclay, A. N., Polymorphisms in the human inhibitory signal-regulatory protein α do not affect binding to its ligand CD47. J. Biol. Chem. 2014. 289: 10024-10028.
Johansen, M. L. and Brown, E. J., Dual regulation of SIRPalpha phosphorylation by integrins and CD47. J. Biol. Chem. 2007. 282: 24219-24230.
Ling, Y., Maile, L. A., Lieskovska, J., Badley-Clarke, J. and Clemmons, D. R., Role of SHPS-1 in the regulation of insulin-like growth factor I-stimulated Shc and mitogen-activated protein kinase activation in vascular smooth muscle cells. Mol. Biol. Cell 2005. 16: 3353-3364.
Sharp, R. C., Brown, M. E., Shapiro, M. R., Posgai, A. L. and Brusko, T. M., The immunoregulatory role of the signal regulatory protein family and CD47 signaling pathway in type 1 diabetes. Front. Immunol. 2021. 12: 739048.
Janssen, W. J., McPhillips, K. A., Dickinson, M. G., Linderman, D. J., Morimoto, K., Xiao, Y. Q., Oldham, K. M. et al., Surfactant proteins A and D suppress alveolar macrophage phagocytosis via interaction with SIRP alpha. Am. J. Respir. Crit. Care Med. 2008. 178: 158-167.
Fournier, B., Andargachew, R., Robin, A. Z., Laur, O., Voelker, D. R., Lee, W. Y., Weber, D. et al., Surfactant protein D (Sp-D) binds to membrane-proximal domain (D3) of signal regulatory protein α (SIRPα), a site distant from binding domain of CD47, while also binding to analogous region on signal regulatory protein β (SIRPβ). J. Biol. Chem. 2012. 287: 19386-19398.
Gardai, S. J., Xiao, Y. Q., Dickinson, M., Nick, J. A., Voelker, D. R., Greene, K. E. and Henson, P. M., By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 2003. 115: 13-23.
Watson, A., Madsen, J. and Clark, H. W., SP-A and SP-D: dual functioning immune molecules with antiviral and immunomodulatory properties. Front. Immunol. 2020. 11: 622598.
Veillette, A. and Chen, J., SIRPα-CD47 immune checkpoint blockade in anticancer therapy. Trends Immunol. 2018. 39: 173-184.
Koh, E., Lee, E. J., Nam, G. H., Hong, Y., Cho, E., Yang, Y. and Kim, I. S., Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis. Biomaterials 2017. 121: 121-129.
Tsai, R. K. and Discher, D. E., Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J. Cell Biol. 2008. 180: 989-1003.
Okazawa, H., Motegi, S., Ohyama, N., Ohnishi, H., Tomizawa, T., Kaneko, Y., Oldenborg, P. A. et al., Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J. Immunol. 2005. 174: 2004-2011.
Jaiswal, S., Jamieson, C. H., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D. et al., CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009. 138: 271-285.
Yi, T., Li, J., Chen, H., Wu, J., An, J., Xu, Y., Hu, Y. et al., Splenic dendritic cells survey red blood cells for missing self-CD47 to trigger adaptive immune responses. Immunity 2015. 43: 764-775.
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., Jr., van Rooijen, N. et al., CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009. 138: 286-299.
Theocharides, A. P., Jin, L., Cheng, P. Y., Prasolava, T. K., Malko, A. V., Ho, J. M., Poeppl, A. G. et al., Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J. Exp. Med. 2012. 209: 1883-1899.
Murata, Y., Tanaka, D., Hazama, D., Yanagita, T., Saito, Y., Kotani, T., Oldenborg, P. A. et al., Anti-human SIRPα antibody is a new tool for cancer immunotherapy. Cancer Sci. 2018. 109: 1300-1308.
Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K. et al., Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci. Transl. Med. 2010. 2: 63ra94.
Chen, J., Zhong, M. C., Guo, H., Davidson, D., Mishel, S., Lu, Y., Rhee, I. et al., SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature 2017. 544: 493-497.
Tang, Z., Davidson, D., Li, R., Zhong, M. C., Qian, J., Chen, J. and Veillette, A., Inflammatory macrophages exploit unconventional pro-phagocytic integrins for phagocytosis and anti-tumor immunity. Cell Rep. 2021. 37: 110111.
Morrissey, M. A., Kern, N. and Vale, R. D., CD47 Ligation repositions the inhibitory receptor SIRPA to suppress integrin activation and phagocytosis. Immunity 2020. 53: 290-302.e296.
Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y. X. and Weissman, I. L., Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat. Rev. Cancer 2019. 19: 568-586.
Barkal, A. A., Weiskopf, K., Kao, K. S., Gordon, S. R., Rosental, B., Yiu, Y. Y., George, B. M. et al., Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat. Immunol. 2018. 19: 76-84.
Pan, C., Zhu, D., Zhuo, J., Li, L., Wang, D., Zhang, C. Y., Liu, Y. et al., Role of signal regulatory protein α in arsenic trioxide-induced promyelocytic leukemia cell apoptosis. Sci. Rep. 2016. 6: 23710.
Wang, X., Li, Y., Zhu, X., Wang, Y., Diao, F. and Lu, J., Signal regulatory protein alpha1 is involved in the inhibitory effect of glucocorticoid receptor on the proliferation of murine macrophage RAW264.7 cell and mouse peritoneal macrophage. J. Mol. Endocrinol. 2008. 41: 393-403.
Maekawa, T., Imoto, A., Satoh, T., Okazaki, T. and Takahashi, S., Induction of β-catenin by the suppression of signal regulatory protein α1 in K562 cells. Int. J. Mol. Med. 2011. 27: 865-872.
Zhang, Y., Sime, W., Juhas, M. and Sjölander, A., Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. Eur. J. Cancer 2013. 49: 3320-3334.
Lin, Y., Zhao, J. L., Zheng, Q. J., Jiang, X., Tian, J., Liang, S. Q., Guo, H. W. et al., Notch signaling modulates macrophage polarization and phagocytosis through direct suppression of signal regulatory protein α expression. Front. Immunol. 2018. 9: 1744.
Hu, J., Xiao, Q., Dong, M., Guo, D., Wu, X. and Wang, B., Glioblastoma immunotherapy targeting the innate immune checkpoint CD47-SIRPα Axis. Front. Immunol. 2020. 11: 593219.
Hutter, G., Theruvath, J., Graef, C. M., Zhang, M., Schoen, M. K., Manz, E. M., Bennett, M. L. et al., Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma. Proc. Natl. Acad. Sci. U. S. A. 2019. 116: 997-1006.
Liu, X., Pu, Y., Cron, K., Deng, L., Kline, J., Frazier, W. A., Xu, H. et al., CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 2015. 21: 1209-1215.
Matlung, H. L., Szilagyi, K., Barclay, N. A. and van den Berg, T. K., The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Immunol. Rev. 2017. 276: 145-164.
de Vries, H. E., Hendriks, J. J., Honing, H., De Lavalette, C. R., van der Pol, S. M., Hooijberg, E., Dijkstra, C. D. et al., Signal-regulatory protein alpha-CD47 interactions are required for the transmigration of monocytes across cerebral endothelium. J. Immunol. 2002. 168: 5832-5839.
Soto-Pantoja, D. R., Terabe, M., Ghosh, A., Ridnour, L. A., DeGraff, W. G., Wink, D. A., Berzofsky, J. A. et al., CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res. 2014. 74: 6771-6783.
Li, Z., He, L., Wilson, K. and Roberts, D., Thrombospondin-1 inhibits TCR-mediated T lymphocyte early activation. J. Immunol. 2001. 166: 2427-2436.
Miller, T. W., Kaur, S., Ivins-O'Keefe, K. and Roberts, D. D., Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation. Matrix Biol. 2013. 32: 316-324.
Deuse, T., Hu, X., Agbor-Enoh, S., Jang, M. K., Alawi, M., Saygi, C., Gravina, A. et al., The SIRPα-CD47 immune checkpoint in NK cells. J. Exp. Med. 2021. 218.
Wong, A. S., Mortin-Toth, S., Sung, M., Canty, A. J., Gulban, O., Greaves, D. R. and Danska, J. S., Polymorphism in the innate immune receptor SIRPα controls CD47 binding and autoimmunity in the nonobese diabetic mouse. J. Immunol. 2014. 193: 4833-4844.
Kobayashi, M., Ohnishi, H., Okazawa, H., Murata, Y., Hayashi, Y., Kobayashi, H., Kitamura, T. et al., Expression of Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 in pancreatic beta-cells and its role in promotion of insulin secretion and protection against diabetes. Endocrinology 2008. 149: 5662-5669.
Westra, H. J., Martínez-Bonet, M., Onengut-Gumuscu, S., Lee, A., Luo, Y., Teslovich, N., Worthington, J. et al., Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes. Nat. Genet. 2018. 50: 1366-1374.
Ide, K., Wang, H., Tahara, H., Liu, J., Wang, X., Asahara, T., Sykes, M. et al., Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages. Proc. Natl. Acad. Sci. U. S. A. 2007. 104: 5062-5066.
Yamauchi, T., Takenaka, K., Urata, S., Shima, T., Kikushige, Y., Tokuyama, T., Iwamoto, C. et al., Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment. Blood 2013. 121: 1316-1325.
Jinnouchi, F., Yamauchi, T., Yurino, A., Nunomura, T., Nakano, M., Iwamoto, C., Obara, T. et al., A human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells. Blood 2020. 135: 1661-1672.
Takenaka, K., Prasolava, T. K., Wang, J. C., Mortin-Toth, S. M., Khalouei, S., Gan, O. I., Dick, J. E. et al., Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat. Immunol. 2007. 8: 1313-1323.
Dai, H., Friday, A. J., Abou-Daya, K. I., Williams, A. L., Mortin-Toth, S., Nicotra, M. L., Rothstein, D. M. et al., Donor SIRPα polymorphism modulates the innate immune response to allogeneic grafts. Sci. Immunol. 2017. 2.
Washio, K., Kotani, T., Saito, Y., Respatika, D., Murata, Y., Kaneko, Y., Okazawa, H. et al., Dendritic cell SIRPα regulates homeostasis of dendritic cells in lymphoid organs. Genes Cells 2015. 20: 451-463.
Pengam, S., Durand, J., Usal, C., Gauttier, V., Dilek, N., Martinet, B., Daguin, V. et al., SIRPα/CD47 axis controls the maintenance of transplant tolerance sustained by myeloid-derived suppressor cells. Am. J. Transplant. 2019. 19: 3263-3275.
Wang, X. X. and Pfenninger, K. H., Functional analysis of SIRPalpha in the growth cone. J. Cell Sci. 2006. 119: 172-183.
Kajiho, Y., Harita, Y., Kurihara, H., Horita, S., Matsunaga, A., Tsurumi, H., Kanda, S. et al., SIRPα interacts with nephrin at the podocyte slit diaphragm. FEBS J. 2012. 279: 3010-3021.
Li, L., Liu, Y., Li, S., Yang, R., Zeng, C., Rong, W., Liang, H. et al., Signal regulatory protein α protects podocytes through promoting autophagic activity. JCI Insight 2019. 5.
Huang, Y., Liu, Z., Cao, B. B., Qiu, Y. H. and Peng, Y. P., Treg cells protect dopaminergic neurons against MPP+ neurotoxicity via CD47-SIRPA interaction. Cell. Physiol. Biochem. 2017. 41: 1240-1254.
Nishimura, T., Saito, Y., Washio, K., Komori, S., Respatika, D., Kotani, T., Murata, Y. et al., SIRPα on CD11c(+) cells induces Th17 cell differentiation and subsequent inflammation in the CNS in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2020. 50: 1560-1570.
Jiang, D., Burger, C. A., Akhanov, V., Liang, J. H., Mackin, R. D., Albrecht, N. E., Andrade, P. et al., Neuronal signal-regulatory protein alpha drives microglial phagocytosis by limiting microglial interaction with CD47 in the retina. Immunity 2022. 55: 2318-2335.e2317.
Huang, F., Yang, C., Yu, W., Bi, Y., Long, F., Wang, J., Li, Y. et al., Hepatitis E virus infection activates signal regulator protein α to down-regulate type I interferon. Immunol. Res. 2016. 64: 115-122.
Sarute, N., Ibrahim, N., Medegan Fagla, B., Lavanya, M., Cuevas, C., Stavrou, S., Otkiran-Clare, G. et al., TRIM2, a novel member of the antiviral family, limits New World arenavirus entry. PLoS Biol. 2019. 17: e3000137.
Sarute, N., Cheng, H., Yan, Z., Salas-Briceno, K., Richner, J., Rong, L. and Ross, S. R., Signal-regulatory protein alpha is an anti-viral entry factor targeting viruses using endocytic pathways. PLoS Pathog. 2021. 17: e1009662.
Singla, B., Lin, H. P., Ahn, W., Xu, J., Ma, Q., Sghayyer, M., Dong, K. et al., Loss of myeloid cell-specific SIRPα, but not CD47, attenuates inflammation and suppresses atherosclerosis. Cardiovasc. Res. 2022. 118: 3097-3111.
Jarr, K. U., Ye, J., Kojima, Y., Ye, Z., Gao, H., Schmid, S., Luo, L. et al., The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis. Nat Cardiovasc Res 2022. 1: 253-262.
Chen, W., Li, X., Wang, J., Song, N., Zhu, A. and Jia, L., miR-378a modulates macrophage phagocytosis and differentiation through targeting CD47-SIRPα axis in atherosclerosis. Scand. J. Immunol. 2019. 90: e12766.
Dubois, N. C., Craft, A. M., Sharma, P., Elliott, D. A., Stanley, E. G., Elefanty, A. G., Gramolini, A. et al., SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat. Biotechnol. 2011. 29: 1011-1018.
Skelton, R. J., Costa, M., Anderson, D. J., Bruveris, F., Finnin, B. W., Koutsis, K., Arasaratnam, D. et al., SIRPA, VCAM1 and CD34 identify discrete lineages during early human cardiovascular development. Stem Cell Res 2014. 13: 172-179.
Liu, Y., Li, M., Wei, C., Tang, L., Sheng, Y., Liu, Y., Li, D. et al., TSP1-CD47-SIRPα signaling facilitates the development of endometriosis by mediating the survival of ectopic endometrium. Am. J. Reprod. Immunol. 2020. 83: e13236.
Beckmann, N., Huber, F., Hanschen, M., St Pierre Schneider, B., Nomellini, V. and Caldwell, C. C., Scald injury-induced t cell dysfunction can be mitigated by Gr1(+) cell depletion and blockage of CD47/CD172a signaling. Front. Immunol. 2020. 11: 876.
Respatika, D., Saito, Y., Washio, K., Komori, S., Kotani, T., Okazawa, H., Murata, Y. et al., Role of SIRPα in homeostatic regulation of T cells and fibroblastic reticular cells in the spleen. Kobe J. Med. Sci. 2017. 63: E22-e29.
Ring, N. G., Herndler-Brandstetter, D., Weiskopf, K., Shan, L., Volkmer, J. P., George, B. M., Lietzenmayer, M. et al., Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 2017. 114: E10578-e10585.
Liu, J., Xavy, S., Mihardja, S., Chen, S., Sompalli, K., Feng, D., Choi, T. et al., Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy. JCI Insight 2020. 5.
Eskiocak, U., Guzman, W., Daly, T., Nelson, A., Bakhru, P., Lajoie, J., Haserlat, S. et al., Abstract 3239: CTX-5861 mediated SIRPα blockade combines with tumor targeting antibodies, checkpoint blockade and/or CD137 agonism to elicit curative anti-tumor activity in syngeneic mouse models. Cancer Research 2019. 79: 3239-3239.
Gauttier, V., Pengam, S., Durand, J., Biteau, K., Mary, C., Morello, A., Néel, M. et al., Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance. J. Clin. Invest. 2020. 130: 6109-6123.
Bian, Z., Shi, L., Kidder, K., Zen, K., Garnett-Benson, C. and Liu, Y., Intratumoral SIRPα-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy. Nat. Commun. 2021. 12: 3229.
Delord, J.-P., Kotecki, N., Marabelle, A., Vinceneux, A., Korakis, I., Jungels, C., Champiat, S. et al., A phase 1 study evaluating BI 765063, a first in class selective myeloid sirpa inhibitor, as stand-alone and in combination with BI 754091, a programmed death-1 (PD-1) inhibitor, in patients with advanced solid tumours. Blood 2019. 134: 1040-1040.
Ingelheim, B., BI 765063 and BI 770371: SIRPα antagonists 2023.
Strati, P., Hawkes, E., Ghosh, N., Tuscano, J. M., Chu, Q., Anderson, M. A., Patel, A. et al., Interim results from the first clinical study of CC-95251, an anti-signal regulatory protein-alpha (SIRPα) antibody, in combination with rituximab in patients with relapsed and/or refractory non-hodgkin lymphoma (R/R NHL). Blood 2021. 138: 2493-2493.
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., Kline, J. et al., CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma. N. Engl. J. Med. 2018. 379: 1711-1721.
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D. et al., First-in-human, first-in-class Phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J. Clin. Oncol. 2019. 37: 946-953.
Narkhede, M., Bartlett, N. L., Ibrahimi, S., Popplewell, L., Seto, A., Bates, J., Lee, Y. et al., A phase 1 first-in-human study of GS-0189, an anti-signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). EJHaem 2023. 4: 370-380.
Yang, J., Deresa, I., Ho, W. H., Long, H., Maslyar, D., Rosenthal, A., Liang, S. C. et al., AL008 enhances myeloid antitumor function by inhibiting SIRPα signaling and activating Fc receptors. J. Immunol. 2023. 210: 204-215.
ClinicalTrials.gov, A study of DS-1103a combination therapy in participants with advanced solid tumors 2023.
Voets, E., Paradé, M., Lutje Hulsik, D., Spijkers, S., Janssen, W., Rens, J., Reinieren-Beeren, I. et al., Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint. J. Immunother. Cancer 2019. 7: 340.
van Helden, M. J., Zwarthoff, S. A., Arends, R. J., Reinieren-Beeren, I. M. J., Paradé, M., Driessen-Engels, L., de Laat-Arts, K. et al., BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells. J. Immunother. Cancer 2023. 11.
Kuo, T. C., Chen, A., Harrabi, O., Sockolosky, J. T., Zhang, A., Sangalang, E., Doyle, L. V. et al., Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity. J. Hematol. Oncol. 2020. 13: 160.
Yu, J., Li, S., Chen, D., Liu, D., Guo, H., Yang, C., Zhang, W. et al., SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don't eat me” signal and activating the “eat me” signal. J. Hematol. Oncol. 2022. 15: 167.